Lyumjev, a rapid-acting mealtime insulin, is available through various discount programs and patient assistance initiatives. For individuals with commercial insurance, the Eli Lilly and Company Savings Card can reduce out-of-pocket costs to as low as $35 per monthly prescription, subject to program terms and conditions [1].
How can I get a discount on Lyumjev?
Several avenues exist for Lyumjev discounts. The Eli Lilly and Company Savings Card is a primary option for those with commercial insurance [1]. For uninsured or underinsured patients who meet specific income requirements, Lilly Cares Foundation provides free medication through its patient assistance program [2]. Prescription discount cards and coupons from third-party providers may also offer savings, though their applicability and discount levels can vary [3].
What is Lyumjev's list price?
The list price of Lyumjev can vary depending on the formulation and quantity prescribed. For instance, a 10-pack of 3mL cartridges might have a list price around $700, and a 5-pack of 3mL pens could be priced near $400 [4]. These figures represent wholesale costs and do not reflect the price paid by patients after insurance or discounts.
When does Lyumjev's patent expire?
The patent landscape for Lyumjev is complex, involving multiple patents related to its formulation and use. According to DrugPatentWatch.com, the earliest expected patent expiry for Lyumjev is around late 2024, with subsequent patents extending further into the future [5]. These dates are subject to ongoing legal challenges and patent term adjustments.
Can biosimilars of Lyumjev be developed?
The development of biosimilars for Lyumjev depends on the expiration of relevant patents and the regulatory pathway. Once key patents expire and are no longer subject to effective legal challenges, companies can pursue the development and approval of biosimilar versions of Lyumjev, potentially increasing competition and lowering costs [5].
What is the difference between Lyumjev and Humalog?
Lyumjev and Humalog are both rapid-acting insulins manufactured by Eli Lilly and Company. Lyumjev is designed for faster absorption and onset of action compared to Humalog. This difference is attributed to its formulation, which includes the excipient treprostinil, allowing it to achieve maximum concentration in the blood more quickly after injection. Clinical studies have shown Lyumjev to be effective in reducing post-meal blood glucose levels [6].
Who makes Lyumjev?
Lyumjev is manufactured by Eli Lilly and Company [1].
What are the side effects of Lyumjev?
Common side effects associated with Lyumjev include hypoglycemia (low blood sugar), injection site reactions, and allergic reactions. Patients should monitor for signs of low blood sugar such as dizziness, sweating, confusion, and rapid heartbeat. Severe allergic reactions are rare but can be life-threatening [7].
How is Lyumjev administered?
Lyumjev is administered via subcutaneous injection into the abdomen, thigh, or upper arm, or via an insulin pump [7].
What is the typical dosage of Lyumjev?
The dosage of Lyumjev is individualized based on the patient's needs, blood glucose levels, and mealtime insulin requirements. It is typically taken before meals or within 20 minutes after starting a meal [7].
Sources:
[1] https://www.lyumjev.com/savings-and-support/lyumjev-savings-card
[2] https://www.lilycares.com/
[3] https://www.goodrx.com/lyumjev
[4] https://www.goodrx.com/lyumjev-prices
[5] https://drugpatentwatch.com/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599670/
[7] https://www.lyumjev.com/